BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Center For Technology Licensing - ECPv6.11.2.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Center For Technology Licensing
X-ORIGINAL-URL:https://ctl.cornell.edu
X-WR-CALDESC:Events for Center For Technology Licensing
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250401T150000
DTEND;TZID=America/New_York:20250401T180000
DTSTAMP:20260524T223818
CREATED:20250312T151532Z
LAST-MODIFIED:20250312T190952Z
UID:10000558-1743519600-1743530400@ctl.cornell.edu
SUMMARY:Weill Cornell Medicine Biomedical Innovation Conference
DESCRIPTION:The 2025 Weill Cornell Medicine Biomedical Innovation Conference brings together academic founders with investors\, industry representatives\, entrepreneurs and ecosystem partners with the expressed goal of finding opportunities to connect and collaborate. The conference is a rare opportunity to meet a diverse group of life science inventors and spinout companies across therapeutics\, device\, digital health and diagnostic sectors. All Weill Cornell Medicine-affiliated inventors are encouraged to participate. In addition\, select startup companies from the Upper East Side ecosystem\, including Rockefeller University\, Memorial Sloan Kettering\, and surrounding hospitals\, as well as startups where faculty serve as CMOs and Scientific Advisors\, are also in attendance. \nOver the years\, this event has been a proven catalyst for direct investment from early-stage investors\, co-development relationships with industry\, and introductions to experienced management teams. Please contact Loren Busby (lob4002@med.cornell.edu) for more information. \nRegister for the event.
URL:https://ctl.cornell.edu/event/weill-biomedical-innovation-conference
LOCATION:Uris Auditorium\, 1300 York Avenue\, New York\, 10065\, United States
CATEGORIES:CTL Events
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240827T053000
DTEND;TZID=America/New_York:20240827T190000
DTSTAMP:20260524T223818
CREATED:20240817T180439Z
LAST-MODIFIED:20240817T184702Z
UID:10000532-1724736600-1724785200@ctl.cornell.edu
SUMMARY:Accelerating Bio Venture Innovation (ABI)
DESCRIPTION:ABI is a 15-week course and training program in biomedical entrepreneurship that builds teams around patented technologies originating from Weill Cornell Medicine and neighboring institutions. Through the program’s experiential format\, participants step into the shoes of startup founders and product innovators. With input from a combination of industry mentors and MBA students\, the teams create business plans in the form of investor pitches. The class culminates in a final pitch event in front of VC judges. \nIf you are interested in participating\, the inaugural ABI class will take place on Tuesday\, August 27\, from 5:30-7pm in Uris Auditorium. The kick-off will feature a lecture and interview with Annie De Groot\, MD\, Founder & CSO of EpiVax\, Inc.\, located in Providence\, RI. EpiVax specializes in computational immunology tools for epitope discovery\, de-immunization\, and vaccine design\, and collaborates closely with the FDA on regulatory methods for generic peptide drugs. Dr. De Groot is the author of over 240 publications and 50 patents and has generated over $35M in US federal funding. \nAnyone interested in joining this program must complete the form available HERE.
URL:https://ctl.cornell.edu/event/accelerating-bio-venture-innovation-abi
LOCATION:Uris Auditorium\, 1300 York Avenue\, New York\, 10065\, United States
CATEGORIES:Cornell Community Events
ATTACH;FMTTYPE=image/jpeg:https://ctl.cornell.edu/wp-content/uploads/2024/08/dr_zhou_2_copy.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230829T173000
DTEND;TZID=America/New_York:20230829T203000
DTSTAMP:20260524T223818
CREATED:20230812T225526Z
LAST-MODIFIED:20230812T225632Z
UID:10000441-1693330200-1693341000@ctl.cornell.edu
SUMMARY:Accelerating BioVenture Innovation Kick-Off
DESCRIPTION:We formally invite you to join Weill Cornell Medicine and the greater NYC life science startup community for the kick-off of our Accelerating BioVenture Innovation accelerator with special guest – Erandi De Silva\, PhD\, Co-Founder & Senior Vice President of Product Development at Forge Biologics!  Dr. De Silva was selected by Fierce Pharma as one of its 2022 Fiercest Women in Life Sciences. We are excited to have her on campus to share her personal story and startup journey. \nThe event is scheduled for Tuesday\, August 29\, 5:30-8:30pm. It will take place in-person at Uris Auditorium\, 1300 York Avenue @ 69th Street\, and will be followed by a networking reception with cocktails in Griffis Faculty Lounge (same location). This is a great opportunity to meet like-minded faculty\, trainees and clinicians interested in translational science and medicine.  \nRegister HERE \n\nAbout Forge Biologics \nForge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge’s mission is to enable access to life-changing gene therapies and help bring them from idea to reality. Forge’s 200\,000 square foot facility utilizes 20 cGMP suites in Columbus\, Ohio\, the Hearth\, to serve as its headquarters. The Hearth is a custom-designed cGMP facility dedicated to AAV manufacturing and hosts scalable\, end-to-end manufacturing services. Offerings include process and analytical development\, plasmid DNA manufacturing\, viral vector manufacturing\, final fill\, as well as regulatory consulting support to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. Investors include Drive Capital\, Perceptive Xontogeny Venture Fund\, RA Capital Management\, Surveyor Capital (a Citadel company)\, Octagon Capital\, Marshall Wace\, and Aisling Capital. By taking a patients-first approach\, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more\, visit www.forgebiologics.com. \n About Accelerating BioVenture Innovation  \nABI is a training program for life science postdocs/trainees\, PhD students\, and medical school students. The 15-week program builds teams around patented technologies from Weill Cornell Medicine\, Memorial Sloan Kettering Cancer Center and Rockefeller University. Teams develop business plans in the form of an investor pitch around these technologies. The teams are matched with MBA students and biotech industry professionals to broaden their business acumen and promote collaboration. Weekly lectures cover various startup fundamentals. At the end of the course\, the teams compete in a final pitch event with institutional VCs and angel investors as judges. If you are interested in participating in this Fall course\, please register here.
URL:https://ctl.cornell.edu/event/accelerating-bioventure-innovation-kick-off
LOCATION:Uris Auditorium\, 1300 York Avenue\, New York\, 10065\, United States
ATTACH;FMTTYPE=image/png:https://ctl.cornell.edu/wp-content/uploads/2023/08/Events-page-image-size-700x500px.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230601T173000
DTEND;TZID=America/New_York:20230601T203000
DTSTAMP:20260524T223818
CREATED:20230428T183503Z
LAST-MODIFIED:20230525T192918Z
UID:10000380-1685640600-1685651400@ctl.cornell.edu
SUMMARY:2023 Biomedical Business Plan Challenge Final Pitch Event
DESCRIPTION:Join the Weill Cornell Medicine community for a night of cocktails and networking to celebrate the successful completion of the Business Plan Challenge program by our ambitious newcos. In this highly selective program\, these faculty-led newcos complete 12 weeks of seminars led by subject matter experts. The topics include market concepts\, intellectual property\, R&D planning\, licensing/partnering\, budgeting/fundraising\, and others. Industry mentors are matched to the teams to support development of their business plans and finalization of their investor pitches. \nWe will kick-off the evening with pitches from each competing newco team\, and a panel of VC judges will choose winners for the $100K prize. Following judge deliberations\, an awards announcement and networking reception will commence. The event takes place on-site at Uris Auditorium and Griffis Faculty Club\, both located at 1300 York Avenue (@ 69th Street)\, New York\, NY 10065 \nAGENDA \n\nWelcome Remarks (Uris Auditorium) – Krystyn J. Van Vliet\, Vice President for Research and Innovation\, Cornell University.\nPitches (Uris Auditorium)\nJudge Deliberations & Awards Ceremony (Griffis Faculty Club)\nReception – Networking with cocktails and hors d’oeuvres (Griffis Faculty Club)\n\nJUDGES \n\nArtavazd (Artie) Arumov\, PhD – Vice President\, Qiming Ventures (US)\nUya Chuluunbaatar\, PhD – Partner\, Avoro Ventures\nSonia Gulati\, PhD – Principal\, Global BioAccess Fund\nCarlo Rizzuto\, PhD – Managing Director\, Versant Ventures\nMisti Ushio\, PhD – Managing Partner\, Digitalis Ventures\nColin (Leyi) Wang\, PhD – Managing Director\, 6 Dimensions Capital\n\nTEAMS \n\nMicroRNA therapeutics to treat obesity and high cholesterol\nCell therapy to treat insulin-dependent diabetes\nTherapeutics to treat multiple myeloma and solid tumors\nStem cell plasticity platform for treating a variety of diseases\nNovel small molecules for the treatment of metabolic diseases and cancer\nSingle-molecule nanoscopy platform for high-throughput\, real-time screening and imaging of live cells to be used in drug discovery\nProprietary therapeutic diet plans to fight against cancer and aging\n\nRegister here.
URL:https://ctl.cornell.edu/event/2023-biomedical-business-plan-challenge-final-pitch-event
LOCATION:Uris Auditorium\, 1300 York Avenue\, New York\, 10065\, United States
CATEGORIES:Cornell Community Events
ATTACH;FMTTYPE=image/png:https://ctl.cornell.edu/wp-content/uploads/2023/04/100K-Business-Plan-Challenge-Flyer-700-×-500-px.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20200319T180000
DTEND;TZID=UTC:20200319T203000
DTSTAMP:20260524T223818
CREATED:20200306T202334Z
LAST-MODIFIED:20200306T202334Z
UID:10000201-1584640800-1584649800@ctl.cornell.edu
SUMMARY:Fireside Chat with Alex Gorsky  Chairman and CEO\, Johnson & Johnson (POSTPONED)
DESCRIPTION:Moderated by Dr. John P. Leonard\nSenior Associate Dean for Innovation and Initiatives\nWeill Cornell Medicine \nFollowed by a presentation from JLABS @ NYC \nThursday\, March 19\, 2020\n6:00-8:30pm\nUris Auditorium\n1300 York Avenue\, New York\, NY 10065 \nAlex Gorsky is Chairman of the Board and Chief Executive Officer of Johnson & Johnson\, one of just seven leaders who have served in the dual role since the company was listed on the New York Stock Exchange in 1944. \nAlex began his Johnson & Johnson career as a sales representative with Janssen Pharmaceutica in 1988. Over the next three decades\, he advanced through positions of increasing responsibility in sales\, marketing\, and management\, culminating in being named CEO and Chairman in 2012. \nLimited Seats: Register here
URL:https://ctl.cornell.edu/event/fireside-chat-with-alex-gorsky-chairman-and-ceo-johnson-johnson
LOCATION:Uris Auditorium\, 1300 York Avenue\, New York\, 10065\, United States
CATEGORIES:Partner Events
END:VEVENT
END:VCALENDAR